CD4 and myeloid sarcoma: Before evaluating the effects of IFNß stimulation, the expression of the steady-state levels of each of the markers of the JAK-STAT signaling pathway was assessed in three cellular subsets (CD4+ T cells, CD8+ T cells, and CD14+ monocytes) in untreated and treated MS patients.